As opposed to non-small-cell lung cancer (NSCLC), where the identification of oncogenic driver mutations and expression levels of PD-L1 is utilized to guide therapeutic decision making, the genetic profiling of SCLC has not identified specific mutational subtypes and PD-L1 expression has not been proven to be a predictive biomarker [2,13,15]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.